Skip to content

ClearPoint Neuro CLPT Net Change in Cash

Net Change in Cash at other companies

Abbott logo
AbbottABT
-$1.72B-58.6%
Boston Scientific logo
Boston ScientificBSX
-$504M-261%
IAR
Integra LifeSciencesIART
$1.76M+124%
Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
-$167.7M-120%
Medtronic logo
MedtronicMDT
-$136M+11.7%
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
$35.76M+241%

Other financials

Income statement

See full
Revenue$12.1M+42.9%
Gross profit$7.8M+51.1%
Operating income-$8.5M-37.6%
Net income-$9.6M-58.5%
EPS (diluted)-$0.32-45.5%

Balance sheet

See full
Cash & equivalents$36.5M+195%
Total debt$63.6M+1,750%
Total equity$18.8M-5.7%
Total assets$93.4M+211%

Cash flow

See full
Operating cash flow-$8.0M-29.1%
CapEx$645.0K+252%
Free cash flow-$8.6M-35.5%

Valuation

See full
Market cap$538.61M+69.2%
Enterprise value$565.68M+82.9%
P/S13.3×+3.4×

Profitability

See full
Gross margin62.3%+1.1pp
Operating margin-65.2%-1.9pp
Net margin-71.6%+8.8pp
FCF margin-65.7%+269pp

Returns & leverage

See full
Return on equity-149.7%+4,074pp
Debt / equity3.4×+3.2×
Current ratio5.8×+2.3×

Where this comes from

Reported directly by ClearPoint Neuro in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: ClearPoint Neuro’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about ClearPoint Neuro's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ClearPoint Neuro's net change in cash?
ClearPoint Neuro (CLPT) reported net change in cash of -$10.46M in Q1 2026.
How has ClearPoint Neuro's net change in cash changed year-over-year?
ClearPoint Neuro's net change in cash decreased by 35.5% year-over-year, from -$7.72M to -$10.46M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.